It is used to stimulate active immunity to hepatitis A virus (HAV) infection in individuals 12 months of age and older.

Hepatitis A virus vaccine is an inactivated vaccine that contains cell culture-adapted, attenuated hepatitis A virus (HAV) and is used to stimulate active immunity to HAV infection.

History of hypersensitivity to the active substances, to any of the excipients listed in section, to neomycin or to formaldehyde.

During pregnancy, Vaqta should be used only if prescribed. The vaccines should be used during pregnancy only if clearly needed.

It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding. Because inactivated vaccines do not multiply within the body, they should not pose any unusual problems for lactating women or their infants.

Adverse dermatologic effects have been reported with less than 1% of hepatitis A vaccine doses and include urticaria, pruritus, and rash. Others: fatigue/asthenia, feeding problems, fussiness, lethargy, fever (37.5°C or higher, low-grade fever lasting 1 day), malaise, anorexia, and nausea.

Primary dose: Adults 18 years of age and older should receive a single 1.0 mL (50U) dose of vaccine at an elected date. Booster dose: Adults 18 years of age and older who received a primary dose should receive a booster dose of 1.0 mL (50U) 6 to 18 months after the first dose. Hepatitis A virus (HAV) antibodies persist for at least 6 years after the second dose (i.e. booster). Based on mathematic modeling duration of antibody persistence is predicted for at least 25 years.